Log in

NASDAQ:CYCN - Cyclerion Therapeutics Stock Price, Forecast & News

$1.96
+0.06 (+3.16 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$1.88
Now: $1.96
$1.96
50-Day Range
$1.71
MA: $3.12
$12.94
52-Week Range
$1.69
Now: $1.96
$21.00
Volume306,875 shs
Average Volume693,315 shs
Market Capitalization$53.84 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
There is no company description available for Cyclerion Therapeutics Inc.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYCN
CUSIPN/A
CIKN/A
Phone857-327-8778

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-115,250,000.00

Miscellaneous

EmployeesN/A
Market Cap$53.84 million
Next Earnings Date2/11/2020 (Estimated)
OptionableNot Optionable

Receive CYCN News and Ratings via Email

Sign-up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter.


Cyclerion Therapeutics (NASDAQ:CYCN) Frequently Asked Questions

What is Cyclerion Therapeutics' stock symbol?

Cyclerion Therapeutics trades on the NASDAQ under the ticker symbol "CYCN."

How were Cyclerion Therapeutics' earnings last quarter?

Cyclerion Therapeutics Inc (NASDAQ:CYCN) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($1.00) earnings per share for the quarter. The company had revenue of $1.40 million for the quarter. View Cyclerion Therapeutics' Earnings History.

When is Cyclerion Therapeutics' next earnings date?

Cyclerion Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for Cyclerion Therapeutics.

What is the consensus analysts' recommendation for Cyclerion Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclerion Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cyclerion Therapeutics.

Has Cyclerion Therapeutics been receiving favorable news coverage?

Media stories about CYCN stock have trended positive on Saturday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cyclerion Therapeutics earned a daily sentiment score of 2.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Cyclerion Therapeutics.

Are investors shorting Cyclerion Therapeutics?

Cyclerion Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 1,260,000 shares, an increase of 5.9% from the October 31st total of 1,190,000 shares. Based on an average daily volume of 349,900 shares, the short-interest ratio is presently 3.6 days. Currently, 4.8% of the shares of the stock are sold short. View Cyclerion Therapeutics' Current Options Chain.

Who are some of Cyclerion Therapeutics' key competitors?

What other stocks do shareholders of Cyclerion Therapeutics own?

Who are Cyclerion Therapeutics' major shareholders?

Cyclerion Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (1.65%), Russell Investments Group Ltd. (0.33%), Squarepoint Ops LLC (0.32%), California State Teachers Retirement System (0.13%), First Trust Advisors LP (0.13%) and California Public Employees Retirement System (0.12%). Company insiders that own Cyclerion Therapeutics stock include Amy W Schulman, Andreas Busch, Mark G Currie and William Huyett. View Institutional Ownership Trends for Cyclerion Therapeutics.

Which major investors are buying Cyclerion Therapeutics stock?

CYCN stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Russell Investments Group Ltd., Squarepoint Ops LLC, California State Teachers Retirement System, First Trust Advisors LP, California Public Employees Retirement System, Broderick Brian C and Barclays PLC. Company insiders that have bought Cyclerion Therapeutics stock in the last two years include Amy W Schulman, Andreas Busch and Mark G Currie. View Insider Buying and Selling for Cyclerion Therapeutics.

How do I buy shares of Cyclerion Therapeutics?

Shares of CYCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cyclerion Therapeutics' stock price today?

One share of CYCN stock can currently be purchased for approximately $1.96.

How big of a company is Cyclerion Therapeutics?

Cyclerion Therapeutics has a market capitalization of $53.84 million. View Additional Information About Cyclerion Therapeutics.

What is Cyclerion Therapeutics' official website?

The official website for Cyclerion Therapeutics is http://www.cyclerion.com/.

How can I contact Cyclerion Therapeutics?

Cyclerion Therapeutics' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at 857-327-8778 or via email at [email protected]


MarketBeat Community Rating for Cyclerion Therapeutics (NASDAQ CYCN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  19 (Vote Outperform)
Underperform Votes:  22 (Vote Underperform)
Total Votes:  41
MarketBeat's community ratings are surveys of what our community members think about Cyclerion Therapeutics and other stocks. Vote "Outperform" if you believe CYCN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYCN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel